Literature DB >> 11827249

Measuring outcomes of type 2 diabetes disease management program in an HMO setting.

Ibrahim Awad Ibrahim1, Jeff Beich, Jaan Sidorov, Robert Gabbay, Lucy Yu.   

Abstract

BACKGROUND: There is a need to evaluate empirical disease management programs used in managing chronic diseases such as diabetes mellitus in managed care settings.
METHODS: We analyzed data from 252 patients with type 2 diabetes before and 1 year after enrollment in a disease management program. We examined clinical indicators such as HbA1C, HDL, LDL, total cholesterol, diastolic blood pressure, and BMI in addition to self-reported health status measured by SF-36 instrument.
RESULTS: All clinical indicators showed statistically and clinically significant improvements. Only vitality and mental health showed statistically significant improvements in health status. Weak to moderate significant correlation between clinical indicators and health status was observed.
CONCLUSIONS: Disease management can be effective at making significant clinical improvements for participants in a mixed-model HMO setting. No strong relationship between clinical indicators and health status was found. Future research is needed using a more specific health status measuring instrument and a randomized clinical trial design.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11827249

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

Review 1.  Quality of life in glaucoma and three other chronic diseases: a systematic literature review.

Authors:  Tim Mills; Simon K Law; John Walt; Patricia Buchholz; Jan Hansen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

2.  Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.

Authors:  Kristina Secnik Boye; Louis S Matza; Alan Oglesby; Karen Malley; Sunny Kim; Risa P Hayes; Robert Brodows
Journal:  Health Qual Life Outcomes       Date:  2006-10-11       Impact factor: 3.186

3.  Effectiveness and safety of Humalog Mix 50/50 versus Humalog Mix 75/25 in Chinese patients with type 2 diabetes.

Authors:  Mohammad Ishraq Zafar; Xinquan Ai; Raja Adeel Shafqat; Feng Gao
Journal:  Ther Clin Risk Manag       Date:  2014-12-19       Impact factor: 2.423

4.  The Association between Medicare Advantage Market Penetration and Diabetes in the United States.

Authors:  Steven W Howard; Stephanie Lazarus Bernell; Jennifer Wilmott; M Faizan Casim; Jing Wang; Lindsey Pearson; Caitlin M Byler; Zidong Zhang
Journal:  Front Public Health       Date:  2015-10-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.